Acumen Pharmaceuticals Inc (ABOS) concluded trading on Thursday at a closing price of $0.90, with 0.49 million shares of worth about $0.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.34% during that period and on April 17, 2025 the price saw a loss of about -8.08%. Currently the company’s common shares owned by public are about 60.09M shares, out of which, 44.28M shares are available for trading.
Stock saw a price change of -11.69% in past 5 days and over the past one month there was a price change of -29.07%. Year-to-date (YTD), ABOS shares are showing a performance of -47.63% which decreased to -74.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.90 but also hit the highest price of $3.92 during that period. The average intraday trading volume for Acumen Pharmaceuticals Inc shares is 243.82K. The stock is currently trading -16.88% below its 20-day simple moving average (SMA20), while that difference is down -26.21% for SMA50 and it goes to -57.54% lower than SMA200.
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) currently have 60.09M outstanding shares and institutions hold larger chunk of about 62.14% of that.
The stock has a current market capitalization of $54.56M and its 3Y-monthly beta is at 0.15. It has posted earnings per share of -$1.70 in the same period. It has Quick Ratio of 6.46 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABOS, volatility over the week remained 11.72% while standing at 10.23% over the month.
Stock’s fiscal year EPS is expected to drop by -31.08% while it is estimated to increase by 26.99% in next year. EPS is likely to grow at an annualized rate of -2.65% for next 5-years, compared to annual growth of -54.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on July 26, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Deutsche Bank stated Acumen Pharmaceuticals Inc (ABOS) stock as a Buy in their note to investors on December 12, 2023, suggesting a price target of $8 for the stock. On July 20, 2023, BofA Securities Resumed their recommendations, while on May 18, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $13. Stock get a Buy rating from BTIG Research on July 15, 2022.
